TR200003108T2 - İlaç kompozisyonları - Google Patents

İlaç kompozisyonları

Info

Publication number
TR200003108T2
TR200003108T2 TR2000/03108T TR200003108T TR200003108T2 TR 200003108 T2 TR200003108 T2 TR 200003108T2 TR 2000/03108 T TR2000/03108 T TR 2000/03108T TR 200003108 T TR200003108 T TR 200003108T TR 200003108 T2 TR200003108 T2 TR 200003108T2
Authority
TR
Turkey
Prior art keywords
pharmaceutical compositions
macrophate
melters
impregnants
thickeners
Prior art date
Application number
TR2000/03108T
Other languages
English (en)
Inventor
Ibuki Rinta
Shimojo Fumio
Ueda Satoshi
Toyoda Toshihiko
Yamanaka Masayuk�
Yoshida Erika
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Publication of TR200003108T2 publication Critical patent/TR200003108T2/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Abstract

Aktif madde olarak trisiklik bilesikler (I) tarafindan temsil edilen makrolit bilesiklerini içeren, yüksek bir kararliliga, mükemmel bir emilebilirlige ve/ ya da çok az tahris etme özelligine sahip olan ilaç kompozisyonlari ya da istege bagli olarak iyilestirici ajanlar ve/ya da kalinlastiricilarla uyumlu olan bunlarin farmasötik olarak uygun olan tuzlari, eriticileri, emdiricileri ve bazlari.
TR2000/03108T 1998-04-27 1999-04-26 İlaç kompozisyonları TR200003108T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11727198 1998-04-27

Publications (1)

Publication Number Publication Date
TR200003108T2 true TR200003108T2 (tr) 2001-02-21

Family

ID=14707636

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03108T TR200003108T2 (tr) 1998-04-27 1999-04-26 İlaç kompozisyonları

Country Status (24)

Country Link
US (2) US6673808B1 (tr)
EP (1) EP1074255B1 (tr)
JP (1) JP3732525B2 (tr)
KR (1) KR100406823B1 (tr)
CN (1) CN1161117C (tr)
AR (1) AR018330A1 (tr)
AT (1) ATE363275T1 (tr)
AU (1) AU749475B2 (tr)
BR (1) BR9910336A (tr)
CA (1) CA2326222C (tr)
DE (1) DE69936195T2 (tr)
ES (1) ES2284248T3 (tr)
HK (1) HK1038884B (tr)
HU (1) HUP0104452A3 (tr)
ID (1) ID29262A (tr)
IL (1) IL139210A (tr)
NO (1) NO20005399D0 (tr)
NZ (1) NZ507345A (tr)
PL (1) PL343627A1 (tr)
RU (1) RU2203058C2 (tr)
TR (1) TR200003108T2 (tr)
TW (1) TW565461B (tr)
WO (1) WO1999055332A1 (tr)
ZA (1) ZA200005378B (tr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
DE60015516T2 (de) * 1999-04-30 2005-12-01 Sucampo Ag Verwendung von makroliden zur behandlung von trockenen augen
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
AU2002250968C1 (en) * 2001-02-19 2018-01-04 Novartis Ag Cancer treatment
GB0108498D0 (en) * 2001-04-04 2001-05-23 Novartis Ag Organic Compounds
AUPR529701A0 (en) * 2001-05-28 2001-06-21 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition
AR038628A1 (es) * 2002-03-04 2005-01-19 Novartis Ag Composicion oftalmica
GB0218996D0 (en) * 2002-08-14 2002-09-25 Novartis Ag Organic compounds
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
BRPI0508440A (pt) 2004-03-03 2007-07-24 Revance Therapeutics Inc composições e métodos para diagnóstico tópico e transporte terapêutico
WO2006001251A1 (ja) * 2004-06-24 2006-01-05 Kowa Co., Ltd. アトルバスタチン外用剤組成物
KR101453963B1 (ko) 2005-03-03 2014-10-22 레반스 테라퓨틱스, 아이엔씨. 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및 방법
WO2007011880A2 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
FR2900052B1 (fr) * 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
CN101288643B (zh) * 2008-06-17 2012-11-14 杨喜鸿 含有他克莫司的凝胶剂组合物及其制备方法和药物应用
WO2010041684A1 (ja) 2008-10-08 2010-04-15 高田製薬株式会社 タクロリムス外用剤
GB0917816D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
GB0917817D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
JP2011102260A (ja) * 2009-11-11 2011-05-26 Takada Seiyaku Kk タクロリムス外用剤
WO2012011192A1 (ja) * 2010-07-23 2012-01-26 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
JP5674786B2 (ja) * 2010-07-23 2015-02-25 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
JP5652795B2 (ja) * 2011-01-31 2015-01-14 国立大学法人大阪大学 皮膚疾患を処置するための外用薬およびその製造方法
CA3165081A1 (en) * 2020-01-24 2021-07-29 Toru Yasuzawa External preparation containing rapamycin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454113A (en) * 1982-09-21 1984-06-12 Scm Corporation Stabilization of oil and water emulsions using polyglycerol esters of fatty acids
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
EP0474126B1 (en) * 1990-09-04 1997-03-19 Fujisawa Pharmaceutical Co., Ltd. Ointments containing tricyclic compound
TW213418B (tr) * 1991-05-02 1993-09-21 Kuko Seiyaku Kk
JPH06128148A (ja) * 1992-04-30 1994-05-10 Dotsuto:Kk 皮膚外用剤
JP2523428B2 (ja) * 1992-12-04 1996-08-07 エスエス製薬株式会社 消炎鎮痛ゲル製剤
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
MX9702699A (es) * 1994-10-26 1997-06-28 Novartis Ag Composiciones farmaceuticas.
ATE279185T1 (de) * 1995-12-28 2004-10-15 Mitsubishi Pharma Corp 2-amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-di l enthaltendes arzneimittel zur topischen anwendung zur behandlung von erkrankungen die durch eine störung des immunsystems hervorgerufen werden
CZ267796A3 (cs) 1996-09-12 1998-04-15 Galena A.S. Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů
TW450810B (en) * 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
US6316473B1 (en) * 1997-04-11 2001-11-13 Fujisawa Pharmaceutical Co., Ltd. Two surfactant-containing medicinal composition

Also Published As

Publication number Publication date
AR018330A1 (es) 2001-11-14
HUP0104452A2 (hu) 2002-03-28
CN1161117C (zh) 2004-08-11
EP1074255A1 (en) 2001-02-07
EP1074255A4 (en) 2002-02-13
ES2284248T3 (es) 2007-11-01
US20020061907A1 (en) 2002-05-23
NO20005399L (no) 2000-10-26
EP1074255B1 (en) 2007-05-30
AU3537299A (en) 1999-11-16
NZ507345A (en) 2002-12-20
TW565461B (en) 2003-12-11
PL343627A1 (en) 2001-08-27
ID29262A (id) 2001-08-16
KR100406823B1 (ko) 2003-11-21
IL139210A0 (en) 2001-11-25
DE69936195D1 (de) 2007-07-12
KR20010042589A (ko) 2001-05-25
CN1307475A (zh) 2001-08-08
US6586444B2 (en) 2003-07-01
WO1999055332A8 (fr) 2000-02-17
HUP0104452A3 (en) 2004-05-28
ZA200005378B (en) 2002-08-23
JP3732525B2 (ja) 2006-01-05
DE69936195T2 (de) 2007-09-13
NO20005399D0 (no) 2000-10-26
HK1038884A1 (en) 2002-04-04
ATE363275T1 (de) 2007-06-15
WO1999055332A1 (fr) 1999-11-04
BR9910336A (pt) 2001-09-25
RU2203058C2 (ru) 2003-04-27
IL139210A (en) 2005-11-20
CA2326222C (en) 2008-09-23
AU749475B2 (en) 2002-06-27
CA2326222A1 (en) 1999-11-04
HK1038884B (zh) 2005-05-06
US6673808B1 (en) 2004-01-06

Similar Documents

Publication Publication Date Title
TR200003108T2 (tr) İlaç kompozisyonları
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
DK1093819T3 (da) Forbindelse og præparat til tilförsel af aktive midler
CY1105953T1 (el) Συνθεσεις για απελευθερωση συνδυασμων φαρμακων
DK1157037T3 (da) GCSF-konjugater
SE9504661D0 (sv) New compounds
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
DK1140993T3 (da) Glycopeptidderivater og farmaceutiske præparater indeholdende dem
BR0211801A (pt) Derivados de 7h-pirrolo[2,3-d]pirimidina
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
MX9700885A (es) Nuevas heteroariloxazolidinonas.
AU2274201A (en) Compounds and compositions for delivering active agents
ATE218582T1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
IL140710A0 (en) Pulmonary delivery of active agents
AR008991A1 (es) Compuestos de dimetil-(3-aril-but-3-enil)-amina, procedimientos para su preparacion y aplicacion de los mismos
TR200200883T2 (tr) 2-ikameli 1,1-bifenil-2-karbonamidler, imalat yöntemleri, ilaç olarak kullanılmaları
BR0007589A (pt) Inibidores da proliferação de células
SE9802208D0 (sv) Novel compounds
PT1121127E (pt) Composicoes farmaceuticas orais contendo buprenorfina
ECSP930933A (es) Composicion farmaceutica y procedimiento para prepararla
DK1056771T3 (da) Streptograminderivater, deres fremstilling og præparater, der indeholder dem
SE9802209D0 (sv) Novel compounds
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
SE9504662D0 (sv) New compounds
DE69727583D1 (de) Vermeidung von gastrointestinaler schädigung